DBV Technologies Welcomes Dr. Philina Lee to Board of Directors
Today, DBV Technologies, a clinical-stage biopharmaceutical company specializing in creating solutions for food allergies, is excited to announce a significant addition to its Board of Directors. Dr. Philina Lee has been appointed as an independent director, stepping in to replace Daniel Soland. Her appointment is pending ratification by shareholders at the next annual meeting.
Dr. Lee’s Background and Expertise
Dr. Philina Lee brings a wealth of experience to DBV Technologies. Prior to joining the company, she held a series of leadership roles at Blueprint Medicines, where she excelled as Chief Commercial Officer. There, she spearheaded the successful launch and growth of AYVAKIT®. Her impressive track record has also seen her on the Board of Directors at Fusion Pharmaceuticals, where she played an integral role on both the Nomination and Governance Committee and the Research and Development Committee.
Commitment to Growth and Innovation
Michel de Rosen, Chairman of the Board, expressed his enthusiasm about Dr. Lee’s appointment. He remarked, "We are pleased to welcome Philina Lee as a new independent director to the Board. Philina’s extensive experience building successful biopharmaceutical organizations and commercializing pharmaceutical products will add tremendous value as the Company moves closer to potential commercialization.” Her insight is especially valued as DBV Technologies continues to pioneer advancements in the treatment of food allergies.
Significance of VIASKIN® Peanut
At the forefront of DBV Technologies' mission is the development of their proprietary VIASKIN® technology. This innovative approach utilizes epicutaneous immunotherapy (EPIT) to expose patients’ immune systems to allergenic proteins without the invasiveness of traditional methods. This technique represents a game-changing development in addressing food allergies, particularly for young children with peanut allergies.
Future Plans for DBV Technologies
DBV Technologies is dedicated to advancing its research and clinical trials, especially focusing on the effectiveness of the VIASKIN® Peanut patch for infants and toddlers aged between 1 to 7 years. This commitment highlights the company's mission to transform the way food allergic individuals manage their conditions, aiming for long-term solutions that enhance their quality of life.
A Vision for Food Allergy Treatment
Dr. Lee articulated her enthusiasm about joining DBV Technologies during this crucial period, stating, "I am honored to join DBV’s Board at such a pivotal time for the Company, as it continues to advance VIASKIN® Peanut for children and toddlers with peanut allergy. I look forward to serving on the Compensation Committee and contributing to DBV’s growth and success.” Her perspective and expertise will undoubtedly play a pivotal role in shaping the company's future paths.
About DBV Technologies
DBV Technologies is headquartered in Châtillon, France, with its North American operations located in Warren, NJ. The company is one of the leaders in the field of food allergy research, focusing on addressing severe allergic reactions through innovative technologies. Their approach, aimed at achieving a non-invasive treatment for food allergies, continues to gain recognition in the healthcare sector.
Investor and Media Contact Information
For those interested in investing or needing further information, please reach out to:
Investor Contact:
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact:
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Frequently Asked Questions
Who is Dr. Philina Lee?
Dr. Philina Lee is a seasoned biopharmaceutical executive, recently appointed as an independent director on the Board of DBV Technologies.
What is VIASKIN® technology?
VIASKIN® is an innovative epicutaneous immunotherapy (EPIT) method designed to address food allergies by introducing allergens through the skin.
Why is the appointment of Dr. Lee significant?
Her extensive experience in the biopharmaceutical industry is expected to guide DBV Technologies towards successful commercialization of their allergy treatments.
What does DBV Technologies focus on?
Their primary focus is on developing treatment options for food allergies, particularly through the VIASKIN® patch technology.
Where is DBV Technologies headquartered?
DBV Technologies is based in Châtillon, France, with operations in North America located in Warren, NJ.
